{
    "2021-02-04": [
        [
            {
                "time": "",
                "original_text": "恒瑞医药今日大宗交易成交97.10万股，成交价102.8元溢价0.0%。",
                "features": {
                    "keywords": [
                        "恒瑞医药",
                        "大宗交易",
                        "成交价"
                    ],
                    "sentiment_score": 0.5,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": ""
                }
            },
            {
                "time": "",
                "original_text": "恒瑞医药现1笔大宗交易共成交9,981.88万元。",
                "features": {
                    "keywords": [
                        "恒瑞医药",
                        "大宗交易",
                        "成交金额"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": ""
                }
            },
            {
                "time": "",
                "original_text": "恒瑞医药连曝行贿案巨额销售费用或转嫁到最需要人文关怀的肿瘤患者身上其他违规处罚。",
                "features": {
                    "keywords": [
                        "恒瑞医药",
                        "行贿案",
                        "销售费用",
                        "违规处罚"
                    ],
                    "sentiment_score": -0.8,
                    "policy_related": "true",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "",
                "original_text": "人民金融·创新药指数涨1.1%|海思科重磅产品获批新适应症，多个全球1类创新药获批临床。",
                "features": {
                    "keywords": [
                        "创新药指数",
                        "海思科",
                        "新适应症",
                        "创新药"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": ""
                }
            },
            {
                "time": "",
                "original_text": "世卫表示癌症对经济影响巨大，恒瑞医药抗肿瘤药为行业领先。",
                "features": {
                    "keywords": [
                        "世卫",
                        "癌症",
                        "恒瑞医药",
                        "抗肿瘤药"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "true",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": ""
                }
            },
            {
                "time": "",
                "original_text": "恒瑞医药（600276.SH）：RSJ10101研究达到主要及关键次要研究终点。",
                "features": {
                    "keywords": [
                        "恒瑞医药",
                        "RSJ10101",
                        "研究终点"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": ""
                }
            },
            {
                "time": "",
                "original_text": "国产PD-1转向大癌肿竞争，瞄准临床一线用药地位。",
                "features": {
                    "keywords": [
                        "国产PD-1",
                        "大癌肿",
                        "临床一线"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": ""
                }
            },
            {
                "time": "",
                "original_text": "第四批集采：平均降价52%，多家外企“消极”应战。",
                "features": {
                    "keywords": [
                        "第四批集采",
                        "平均降价",
                        "外企"
                    ],
                    "sentiment_score": -0.6,
                    "policy_related": "true",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "",
                "original_text": "A股融资融券日报：两融余额减少13.1亿元（2月3日）。",
                "features": {
                    "keywords": [
                        "A股",
                        "融资融券",
                        "两融余额"
                    ],
                    "sentiment_score": -0.4,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "金融"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "",
                "original_text": "医药行业重大事项点评：第四批带量采购拟中选结果产生降价幅度符合预期。",
                "features": {
                    "keywords": [
                        "医药行业",
                        "带量采购",
                        "拟中选结果",
                        "降价幅度"
                    ],
                    "sentiment_score": 0.5,
                    "policy_related": "true",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": ""
                }
            }
        ]
    ]
}